These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Stabilization of tetanus toxoid formulation containing aluminium hydroxide adjuvant against agitation. Solanki VA; Jain NK; Roy I Int J Pharm; 2012 Feb; 423(2):297-302. PubMed ID: 22155287 [TBL] [Abstract][Full Text] [Related]
7. Forced degradation of therapeutic proteins. Hawe A; Wiggenhorn M; van de Weert M; Garbe JH; Mahler HC; Jiskoot W J Pharm Sci; 2012 Mar; 101(3):895-913. PubMed ID: 22083792 [TBL] [Abstract][Full Text] [Related]
8. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01. Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813 [TBL] [Abstract][Full Text] [Related]
9. Freeze-thaw stress of Alhydrogel ® alone is sufficient to reduce the immunogenicity of a recombinant hepatitis B vaccine containing native antigen. Clapp T; Munks MW; Trivedi R; Kompella UB; Braun LJ Vaccine; 2014 Jun; 32(30):3765-71. PubMed ID: 24856785 [TBL] [Abstract][Full Text] [Related]
10. Long-term stability of morphine hydrochloride in 0.9% NaCl infusion polyolefin bags after freeze-thaw treatment and in polypropylene syringes at 5 degrees C + 3 degrees C. Hecq JD; Godet M; Gillet P; Jamart J; Galanti L Int J Pharm Compd; 2014; 18(1):78-82. PubMed ID: 24881344 [TBL] [Abstract][Full Text] [Related]
11. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. Maa YF; Zhao L; Payne LG; Chen D J Pharm Sci; 2003 Feb; 92(2):319-32. PubMed ID: 12532382 [TBL] [Abstract][Full Text] [Related]
12. Forced degradation studies of biopharmaceuticals: Selection of stress conditions. Tamizi E; Jouyban A Eur J Pharm Biopharm; 2016 Jan; 98():26-46. PubMed ID: 26542454 [TBL] [Abstract][Full Text] [Related]
13. Forced Degradation of Monoclonal Antibodies After Compounding: Impact on Routine Hospital Quality Control. Jaccoulet E; Daniel T; Prognon P; Caudron E J Pharm Sci; 2019 Oct; 108(10):3252-3261. PubMed ID: 31201907 [TBL] [Abstract][Full Text] [Related]
14. Micro/nanoparticle adjuvants: preparation and formulation with antigens. Malyala P; Singh M Methods Mol Biol; 2010; 626():91-101. PubMed ID: 20099123 [TBL] [Abstract][Full Text] [Related]
15. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations. Garidel P; Pevestorf B; Bahrenburg S Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339 [TBL] [Abstract][Full Text] [Related]
16. Assessing Antigen-Adjuvant Complex Stability Against Physical Stresses By wNMR. Taraban MB; Briggs KT; Yu YB; Jones MT; Rosner L; Bhambhani A; Williams DM; Farrell C; Reibarkh M; Su Y Pharm Res; 2023 Jun; 40(6):1435-1446. PubMed ID: 36414838 [TBL] [Abstract][Full Text] [Related]
17. The Production of a Stable Infliximab Powder: The Evaluation of Spray and Freeze-Drying for Production. Kanojia G; Have RT; Bakker A; Wagner K; Frijlink HW; Kersten GF; Amorij JP PLoS One; 2016; 11(10):e0163109. PubMed ID: 27706175 [TBL] [Abstract][Full Text] [Related]
20. Physico-chemical analysis of several injectable drug in ready-to-use infusion after microwave freeze-thaw treatment and final storage at 5 ± 3 °C. Hecq JD; Vanbeckbergen D; Jamart J; Galanti L Ann Pharm Fr; 2011 Sep; 69(5):270-6. PubMed ID: 21924128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]